Discover and read the best of Twitter Threads about #XBB
Most recents (24)
#JustPublished!
A joint #ECDC - @EMA_News statement on updating #COVID19 vaccines composition for new #SARSCoV2 virus variants.
Read full here:
bit.ly/42wARAa
A joint #ECDC - @EMA_News statement on updating #COVID19 vaccines composition for new #SARSCoV2 virus variants.
Read full here:
bit.ly/42wARAa
Como a China pode chegar a 65 milhões de casos de COVID-19 por semana?
Mesmo que a emergência sanitária tenha chegado ao fim no mundo, ainda estamos em pandemia, e o vírus circula muito em muitas regiões do mundo. Nesse mini-fio, algumas razões 👇🏼🧶
noticias.uol.com.br/ultimas-notici…
Mesmo que a emergência sanitária tenha chegado ao fim no mundo, ainda estamos em pandemia, e o vírus circula muito em muitas regiões do mundo. Nesse mini-fio, algumas razões 👇🏼🧶
noticias.uol.com.br/ultimas-notici…
Antes, lembrem que já tivemos anteriormente, logo após a política de abertura da China, estimativas preocupantes de elevação de óbitos por conta da baixa cobertura vacinal em idosos. Até Nov/22 essa cobertura pra 3 doses não era nem de 50% entre os 80+
bbc.com/news/63798484
bbc.com/news/63798484
Existiu também nessa época do fim do ano passado e início desse ano, uma discussão sobre o uso de vacinas de RNAm para vacinar a população mais suscetível a doença, no intuito de elevar os níveis de proteção dessa população nucleo.jor.br/poligono/2022-…
OK, let's pause to reflect on some details here.
The PRC🇨🇳 govt is not denying a dire prediction that the #SARSCoV2 #XBB variants have, for the first time, hit #China and will cause a massive epidemic over the next 6-to-8 weeks.
bloomberg.com/news/articles/…
MORE
The PRC🇨🇳 govt is not denying a dire prediction that the #SARSCoV2 #XBB variants have, for the first time, hit #China and will cause a massive epidemic over the next 6-to-8 weeks.
bloomberg.com/news/articles/…
MORE
BREAKING🔔 The 21st paper from G2P-Japan🇯🇵 is out at Nature Communications @NatureComms . We illuminated the virological characteristics of SARS-CoV-2 XBB variant (aka #Gryphon), generated by the recombination of two #Omicron subvariants. Please RT! 1/
nature.com/articles/s4146…
nature.com/articles/s4146…
In late 2022, the Omicron subvariants have highly diversified. An example is BQ.1.1, which have convergently acquired amino acid substitutions at five critical residues in the spike protein: R346T, K444T, L452R, N460K & F486V. We reported it as below⬇️ 2/
Another variant of concern is XBB. First, two young talents, @jampei2 & @SpyrosLytras, showed that XBB emerged by recombination of two co-circulating BA.2 lineages, BJ.1 & BM.1.1.1 (a progeny of BA.2.75), during summer 2022. 3/
„Der technische Unterausschuss der WHO für die Auswahl von Impfstämmen hat sich letzte Woche auf eine Empfehlung geeinigt, den ursprünglichen #SARSCoV2-Wildtyp-Stamm zu entfernen. Ich bin ziemlich sicher, dass diese Empfehlung den Weg zum VRBPAC finden wird.“
#COVID19 #Corona
#COVID19 #Corona
➡️ Unsere Ergebnisse deuten darauf hin, dass der Ahnenstamm im derzeitigen bivalenten #COVID19-Impfstoff die Ursache für eine tiefe immunologische Prägung ist. Seine Entfernung aus künftigen Impfstoffzusammensetzungen wird daher dringend empfohlen.
biorxiv.org/content/10.110…
biorxiv.org/content/10.110…
Die rekombinanten hochgradig immunevasiven #XBB-Varianten zeigen deutlich, dass wir uns mit der derzeitigen #Corona-Situation nicht abfinden dürfen.
Die Überlastung der Spitäler ist ein völlig unzureichender Massstab für die immensen gesundheitlichen Schäden, die weltweit 1/4
Die Überlastung der Spitäler ist ein völlig unzureichender Massstab für die immensen gesundheitlichen Schäden, die weltweit 1/4
durch #Covid19 verursacht werden.
Entgegen der anfänglichen Ansicht vieler Experten hat #SARSCOV2
ein riesiges Mutationspotential.
Die ungebremste wiederholte #Durchseuchung der Bevölkerung resultiert in vielen chronisch Infizierten, die ein Reservoir für Evolutionssprünge 2/4
Entgegen der anfänglichen Ansicht vieler Experten hat #SARSCOV2
ein riesiges Mutationspotential.
Die ungebremste wiederholte #Durchseuchung der Bevölkerung resultiert in vielen chronisch Infizierten, die ein Reservoir für Evolutionssprünge 2/4
Es wird zunehmend über #SARSCoV2-Omicron-Reinfektionen innerhalb kurzer Zeiträume berichtet. Die Daten dieser Studie aus 🇩🇪, bei der Speichel- und Plasma-Antikörperspiegel bei Kindern und Jugendlichen nach Primärinfektion mit #Omicron-Varianten untersucht wurden,…
#COVID19 #XBB
#COVID19 #XBB
legen nahe, dass dies durch eine schwache humorale Immunantwort auf Omicron erklärt werden könnte. Im Gegensatz zu den Prä-Omicron-Varianten löste eine primäre Omicron-Infektion nur eine schwache IgG-Antikörperreaktion aus, was möglicherweise zu einer unzureichenden
Infektionsprävention durch Speichel-IgG führte. Die beobachtete Neutralisierungsflucht von Omicron-Varianten ist möglicherweise eher auf das Fehlen von Antikörpern als auf eine geringere Bindungsaffinität zurückzuführen. Infolgedessen könnten SARS-CoV-2-Erstinfektionen mit der
THREAD : SUIVI #COVID19
⚠️ Nouvelle règle !
Le dépistage à l'hôpital du covid-19 pour tous les patients n'est plus obligatoire.
Outre le fait qu'on pourra vous coller un COVID+ contagieux peu symptomatique dans votre chambre, cela va fausser
#Covid19 #Enfants #Ecole
1/6
⚠️ Nouvelle règle !
Le dépistage à l'hôpital du covid-19 pour tous les patients n'est plus obligatoire.
Outre le fait qu'on pourra vous coller un COVID+ contagieux peu symptomatique dans votre chambre, cela va fausser
#Covid19 #Enfants #Ecole
1/6
#santépublique #prévention
"Je m'inquiète moins du #SARSCoV2 #XBB ou d'1 super-variant chinois que de l'incapacité des décideurs à apprendre : nous devons investir dans la prévention de la propagation du virus, mettre en œuvre des stratégies permanentes contre la transmission
1/
"Je m'inquiète moins du #SARSCoV2 #XBB ou d'1 super-variant chinois que de l'incapacité des décideurs à apprendre : nous devons investir dans la prévention de la propagation du virus, mettre en œuvre des stratégies permanentes contre la transmission
1/
par voie aérienne et rendre les sociétés résistantes à la #pandémie."
Et ça n'est pas n'importe qui qui vous le demande mais une virologiste spécialistes des virus emergents
().
Au lieu de celà que constatons-nous ?
🔹une mise en danger de mort des plus
2/
Et ça n'est pas n'importe qui qui vous le demande mais une virologiste spécialistes des virus emergents
().
Au lieu de celà que constatons-nous ?
🔹une mise en danger de mort des plus
2/
fragiles qui ne peuvent se protéger seuls et à qui la moindre infection peut être fatale (cf. ce 🧵sur le décès du professeur Greg Folley
) ; vulnérables placés devant des choix cornéliens rester confinés chez eux et renoncer le cas échéant à des soins
3/
) ; vulnérables placés devant des choix cornéliens rester confinés chez eux et renoncer le cas échéant à des soins
3/
Our new preprint on the durability of #bivalent #mRNA vaccines against #XBB.1.5 is out now! We looked at both humoral & cellular immune responses up to 3 months post boost! @BarouchLab @airisyc @ocpowers5599 @mrowe1625
TL;DR: PLEASE GET A BOOSTER!
biorxiv.org/content/10.110…
TL;DR: PLEASE GET A BOOSTER!
biorxiv.org/content/10.110…
We first looked at the nAbs induced by bivalent mRNA vaccines against BQ.1.1, XBB.1, and XBB.1.5 at baseline, 3-weeks-post boost and 3 months post boost. nAb levels peaked at week 3 post-boost, but waned over a period of time.
We also looked at CD4 and CD8 T cell responses post boost, and found at least a 2-fold increment in CD8T cells specific to BQ.1.1 and XBB.1.5, but not as much for WA_1! What does this mean for T cells? Do they have a more pronounced role than previously understood?
Exciting news!
Novavax is working on an Omicron XBB specific vaccine with data expected to be presented at this month's FDA VRBPAC meeting.
Unlike Pfizer and Moderna #Novavax hasn’t yet updated its vaccine to specifically target more recently circulating strains of the virus.
1/
Novavax is working on an Omicron XBB specific vaccine with data expected to be presented at this month's FDA VRBPAC meeting.
Unlike Pfizer and Moderna #Novavax hasn’t yet updated its vaccine to specifically target more recently circulating strains of the virus.
1/
“Up through BA.5, our immune responses had held steady,” said Filip Dubovsky, Novavax’s chief medical officer.
“I can tell you right now that this #xbbvariant XBB, XBB.1, it looks different to us.”
2/
#kraken #XBB #XBB15 $NVAX
barrons.com/articles/novav…
“I can tell you right now that this #xbbvariant XBB, XBB.1, it looks different to us.”
2/
#kraken #XBB #XBB15 $NVAX
barrons.com/articles/novav…
Dubovsky said that Novavax has begun making the so-called viral seed needed to begin the manufacturing process for an updated version of its vaccine that would target XBB.1.1.5
#Novavax will present data on the XBB family of viruses at an advisory committee hearing this month
3/
#Novavax will present data on the XBB family of viruses at an advisory committee hearing this month
3/
#JustPublished!
Threat Assessment Brief: Implications for the EU/EEA of the spread of the #SARSCoV2 #Omicron XBB.1.5 sub-lineage.
Overall level of risk is low for the EU/EEA general population; moderate to high for vulnerable individuals.
Read:
bit.ly/XBB15TAB
#COVID19
Threat Assessment Brief: Implications for the EU/EEA of the spread of the #SARSCoV2 #Omicron XBB.1.5 sub-lineage.
Overall level of risk is low for the EU/EEA general population; moderate to high for vulnerable individuals.
Read:
bit.ly/XBB15TAB
#COVID19
Mathematical modelling indicates that #XBB15 could become dominant in the EU/EEA after 1-2 months, given the current low proportions reported in the EU/EEA & its estimated growth rate.
No signals of increased severity of XBB.1.5 compared to circulating omicron sub-lineages.
No signals of increased severity of XBB.1.5 compared to circulating omicron sub-lineages.
The proportion of XBB.1.5 in EU/EEA was lower than 2.5% for the final 2 weeks of '22 (the most recent period where variant proportions at this low level can be accurately estimated).
In the US, #XBB15 is currently spreading 12% faster than other variants.
bit.ly/XBB15TAB
In the US, #XBB15 is currently spreading 12% faster than other variants.
bit.ly/XBB15TAB
Another huge increase in #COVID19 particles detected in wastewater. This shows that the virus is widely circulating again
Hospitalizations are also up. Though at least for now, not two weeks in a row of sharp increases. This could be in part because of better immunity relative to last year. Or, because wastewater is an early indicator, we just haven't seen the hospital wave yet
The other huge increase is that the new #XBB variant is beginning to show up in a big way now
1/ This @WSJ column implying vaccines fuel bad new variants such as #XBB.1.5 cries out for a re-analysis. I'm not talking about my own competing view but one informed by conversations with the A-team on evolution: @roby_bhatt @LubanLab and @jbloom_lab wsj.com/articles/are-v…
2/ It's correct that the main selective pressure driving evolution of the virus is our immunity, and the only variants to spread now will be ones that can get past it.....
3/ But if not for vaccines the virus would evolve to evade infection-induced immunity. Worldwide, infection-induced immunity is probably a bigger driver than vaccine-induced immunity
Die aktuelle #COVID19-Welle, bei der XBB.1.5 das Infektionsgeschehen im Nordosten der 🇺🇸 mit etwa 75% Anteil dominiert, führt in New York zu einem deutlichen Anstieg der Hospitalisierungen, insbesondere bei den Senioren. In Deutschland könnte XBB.1.5…
#Corona #ImpfenSchuetzt
#Corona #ImpfenSchuetzt
im Februar zur dominierenden Variante werden. XBB.1.5 gehört zu den bisher am stärksten immunevasiven Varianten und verfügt über eine sehr hohe ACE2-Bindungsfähigkeit, was für das Eindringen in menschliche Zellen relevant ist. Die Daten aus USA zeigen, dass sich XBB.1.5 viel
New data show the #COVID19 variant #XBB.1.5 is projected to make up 40.5% of COVID-19 cases nationally. See thread below for what we currently know and on what you can do to protect yourself.
See COVID Data Tracker: bit.ly/3BOwX9Q
See COVID Data Tracker: bit.ly/3BOwX9Q
#COVID19 variant #XBB.1.5 may be more transmissible than other variants, but we don’t know if it causes more severe disease. We’re closely watching this variant to see how well our vaccines & treatments are working against it.
CDC constantly monitors for and reports on current and new COVID-19 variants. As more genetic sequencing data are gathered week to week, today's projections may change. But our advice on protecting yourself from #COVID19 does not.
More on variants: bit.ly/3G6eckZ
More on variants: bit.ly/3G6eckZ
⚠️NEXT BIG ONE—CDC has royally screwed up—unreleased data shows #XBB15, a super variant, surged to 40% US (CDC unreported for weeks!) & now causing hospitalization surges in NY/NE.➡️XBB15–a new recombinant strain—is both more immune evasive & better at infecting than #BQ & XBB.🧵
2) Multiple models show #XBB15 is much worse in transmission R value and infection rate than previous variants — faster by LEAPS and BOUNDS. @JPWeiland did some the earliest models on #XBB15 watching data in NY. it has only grown worse nationwide.
3) in fact, when @JPWeiland first modeled #XBB15 before Xmas, the data shows XBB15 was 108% faster than the previously king #BQ1 variant. But with more data, XBB15 has further accelerated to now being 120% faster!
BREAKING🔔 The 15th preprint from G2P-Japan🇯🇵 is out @biorxivpreprint. We illuminated the virological characteristics of one of the latest SARS-CoV-2 lineages of concern, XBB, which was generated by recombination of two #Omicron subvariants. Please RT. 1/
biorxiv.org/content/10.110…
biorxiv.org/content/10.110…
In late 2022, the Omicron subvariants have highly diversified. An example is BQ.1.1, which has convergently acquired amino acid substitutions at five critical residues in the spike protein: R346T, K444T, L452R, N460K & F486V. We reported it as below⬇️ 2/
Another variant of concern is XBB (aka #gryphon). First, two young talents, @jampei2 & @SpyrosLytras, showed that XBB emerged by recombination of two co-circulating BA.2 lineages, BJ.1 & BM.1.1.1 (a progeny of BA.2.75), during 2022 summer in India or its neighboring countries. 3/
REPEALED—The FDA has now withdrawn authorization of the last #COVID19 MAB drug bebtelovimab, citing it is not expected to neutralize the dominant BQ.1 & BQ.1.1 subvariants. This takes away the last COVID monoclonal antibody treatment. Losing the tools! fda.gov/drugs/drug-saf…
2) For treatment of COVID, this was the last MAB. While Evusheld is still authorized, it’s for pre-exposure prophylaxis (prevention) in limited people. But even then it has limited efficacy against the newer #BA5 Omicron variants.
reuters.com/business/healt…
reuters.com/business/healt…
3) Earlier in October, FDA already warned doctors prescribing @AstraZeneca's Evusheld to inform patients of
"increased risk for developing COVID-19 when exposed to variants of SARS-CoV-2 that are not neutralized" fda.gov/drugs/drug-saf…
"increased risk for developing COVID-19 when exposed to variants of SARS-CoV-2 that are not neutralized" fda.gov/drugs/drug-saf…
Die Entwicklung von #SARSCoV2, nach Omicron
Nach dem Auftreten und der weltweiten Verbreitung der Omicron-Linie BA.5 kam es zu einer beispiellosen Diversifizierung der Omicron-Unterlinien. In diesem Bericht werden die verschiedenen Evolutionspfade…
#COVID19 #CovidIsNotOver
Nach dem Auftreten und der weltweiten Verbreitung der Omicron-Linie BA.5 kam es zu einer beispiellosen Diversifizierung der Omicron-Unterlinien. In diesem Bericht werden die verschiedenen Evolutionspfade…
#COVID19 #CovidIsNotOver
und Mechanismen beschrieben, die zur Entstehung dieser Sublinien geführt haben, und Beispiele für die jeweils am weitesten verbreiteten Linien gegeben, wobei Themen wie BA.2-Linien der zweiten Generation, einfache und komplexe Rekombination, Antigen-Drift und konvergente
Evolution behandelt werden.
Gegenwärtig scheinen BQ.1.1, XBB und CH.1.1 die weltweit am schnellsten wachsenden Varianten zu sein, und es wird erwartet, dass sie in den kommenden Monaten entweder zusammen oder einzeln eine gewisse Anzahl von Infektionswellen auslösen werden.
Gegenwärtig scheinen BQ.1.1, XBB und CH.1.1 die weltweit am schnellsten wachsenden Varianten zu sein, und es wird erwartet, dass sie in den kommenden Monaten entweder zusammen oder einzeln eine gewisse Anzahl von Infektionswellen auslösen werden.
🎉CoVariants.org Update!🎉
22F (XBB) is now available on CoVariants! It's visible as part of Per Country & Per Variant plots, on the shared mutation page - and of course, has a page of its own.
1/9
#XBB #22F
22F (XBB) is now available on CoVariants! It's visible as part of Per Country & Per Variant plots, on the shared mutation page - and of course, has a page of its own.
1/9
#XBB #22F
This is in line with the recent addition of 22F (XBB) as a @nextstrain clade - read more on that below! 👇🏻
2/9
2/9
As I tweeted earlier, 22F (XBB) is a recombinant variant - the first officially elevated using the Nextstrain clade designations. You can read more about what that means in the thread below!
3/9
3/9
1/9 – Nov 06 to Nov 12 –
"Around the #COVID19 World in 80 Seconds"!
Daily epidemic 7-day forecasting for 300+ countries/ territories on our dashboard:tinyurl.com/COVIDdashb
Data source: coronavirus.jhu.edu & ourworldindata.org/coronavirus
Powered by @ISG_UNIGE & @SDSCdatascience
"Around the #COVID19 World in 80 Seconds"!
Daily epidemic 7-day forecasting for 300+ countries/ territories on our dashboard:tinyurl.com/COVIDdashb
Data source: coronavirus.jhu.edu & ourworldindata.org/coronavirus
Powered by @ISG_UNIGE & @SDSCdatascience
2/9 – Western Europe
The #COVID19 epidemic activity is:
- Plateauing/slow landing in: SE (R-eff=1.02);ICL=1.0; GR=1.0; NL=0.96/FL=0.94; PT=0.91.
- Landing in CH; LUX; IT: with low mortality;
AU; DK; FR: medium mortality;
DE: high mortality);
The #COVID19 epidemic activity is:
- Plateauing/slow landing in: SE (R-eff=1.02);ICL=1.0; GR=1.0; NL=0.96/FL=0.94; PT=0.91.
- Landing in CH; LUX; IT: with low mortality;
AU; DK; FR: medium mortality;
DE: high mortality);
3/9 – East-Central Europe
- Landing towards their #COVID19 safety zones in Slovenia; Serbia; Latvia; CZ; Bulgaria; Ukraine;
- Slow landing in Croatia=0.93; Estonia=0.92; Lithuania=0.91.
- Landing towards their #COVID19 safety zones in Slovenia; Serbia; Latvia; CZ; Bulgaria; Ukraine;
- Slow landing in Croatia=0.93; Estonia=0.92; Lithuania=0.91.
Nächste Schritte für nasale Impfstoffe
Philanthropische Organisationen wie CEPI (Coalition for Epidemic Preparedness Innovations), der Wellcome Trust und die Bill and Melinda Gates Foundation veranstalten Anfang November einen Workshop, um Wege zu finden,
#COVID19 #Corona
Philanthropische Organisationen wie CEPI (Coalition for Epidemic Preparedness Innovations), der Wellcome Trust und die Bill and Melinda Gates Foundation veranstalten Anfang November einen Workshop, um Wege zu finden,
#COVID19 #Corona
die Lücke zwischen Tier- und Humanstudien zu nasalen Impfstoffen zu schließen. Die Gruppen konzentrieren sich darauf, nachhaltige und breit anwendbare Impfstoffstrategien zur Bekämpfung von Infektionskrankheiten zu finden - einschließlich eines Pan-Coronavirus-Impfstoffs,
der auf mehrere und potenziell zukünftige Stämme abzielt - und ein nasaler Ansatz ist eine davon.
CEPI ist eine Partnerschaft mit den U.S. National Institutes of Health eingegangen, um die Grundlagenforschung zu mukosalen COVID-19-Impfstoffen zu unterstützen, und gab im Oktober
CEPI ist eine Partnerschaft mit den U.S. National Institutes of Health eingegangen, um die Grundlagenforschung zu mukosalen COVID-19-Impfstoffen zu unterstützen, und gab im Oktober
